



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Phone: 03-3817-5120

Fax: 03-3811-3077

*Eisai is a Human Health Care Corporation striving for innovative
amilies to enhance the quality of life.*

FOR IMMEDIATE RELEASE

No. 08-35

May 22, 2008

Eisai Co., Ltd.

**NON-IONIC CONTRAST AGENTS, IOMERON[®] 350 AND IOMERON[®] 350 SYRINGE,
RECEIVE APPROVAL FOR USE IN DYNAMIC CT LIVER IMAGING**

Bracco-Eisai Co., Ltd. (Headquarters: Tokyo, President: Osamu Hirano), an associate company of Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito), announced that its non-ionic contrast agents, *Iomeron[®] 350* and *Iomeron[®] 350 syringe* (generic name: iomeprol), received additional approval for usage in dynamic computed tomography of the liver imaging (dynamic CT). In addition, a higher dose administration of *Iomeron[®] 350 syringe* (135 ml formulation) also received approval. (135 ml has not yet been added to the National Health Insurance price listing)

Tumors in the liver are generally diagnosed with a dynamic CT by utilization of a multi-slice CT which has been popular in medical instructions recently. This diagnostic method allows a rapid and clear visualization of the entire liver within the holding of one breath. However, there has been a clinical need for a high concentration contrast agent that can be administered in a relatively short period of time. In addition, medical institutions have also desired a contrast agent with a higher dosage administration to better meet specialty patient needs.

Iomeron[®] 350 and *Iomeron[®] 350 syringe* are high concentration formulations of *Iomeron[®]*. The approval announced today will allow the intravenous administration at 1.8 ml/kg, and the dosage can be adjusted depending on the patient's weight (up to 135 ml). With these new formulations, contrast agent can be rapidly administered at the time of dynamic CT imaging using the multi-slice CT and patients with a higher body mass index can receive sufficient dosage for optimum imaging. A post-marketing surveillance will be conducted for the newly approved indication and dosage as an integral component of pharmacovigilance efforts to ensure safe usage of the products.

With this new indication and new high dose formulation of *Iomeron[®]*, Eisai and Bracco-Eisai will make further contributions to the improvement of liver disease diagnosis by dynamic CT imaging using the multi-slice CT as well as to decreasing patients' burdens associated with such diagnostic procedures.

[Please refer to the following notes for terminology and the product]

Contact:
Corporate Communications Department
Eisai Co., Ltd.
81-3-3817-5120

<Note to Editor>

1. About Dynamic Computed Tomography of the Liver/ Multi-Slice CT

Dynamic Computed Tomography of the Liver

